Covid19
Conditions
Keywords
SARS-CoV-2, intensive care, neurocognitive disorders, cognitive dysfunction, biochemical and structural brain changes
Brief summary
Critically ill patients requiring intensive care suffer to a large extent from cognitive deficits involving higher brain functions that primarily affect memory, learning and the ability to concentrate. While the background to this effect is not fully understood, there are growing evidence to support mechanisms related to neuro inflammation and changes in blood flow with concomitant ischemic brain damage. Patients with covid-19 often suffer from severe inflammatory activity with an increased risk of coagulation abnormalities and brain damage. Covid-19 patients requiring intensive care develope more severe impairment of neurological and cognitive function than critically ill intensive care patients who have not covid-19. This project therefore aims to map the link between inflammation, immunology and coagulation systems as well as biochemical and structural changes in the brain with cognitive effects in patients in intensive care for covid-19.
Interventions
None listed
Sponsors
Karolinska Institutet
Karolinska University Hospital
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Age ≥18 years * Need for Intensive care * Positive PCR test for SARS-CoV-2
Exclusion criteria
* None
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The association between changes in blood biomarkers for inflammation and the presence of neuroradiologically verified brain injury and neurocognitive disorder | Up to 12 months |
| The association between changes in blood biomarkers for nerve cell damage and the presence of neuroradiologically verified brain injury and neurocognitive disorder | Up to 12 months |
| The association between changes in blood biomarkers for neurodegeneration and the presence of neuroradiologically verified brain injury and neurocognitive disorder | Up to 12 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Blood biomarker changes of inflammation impact | Up to 3 months | Markers of inflammation impact - in relation to cerebrospinal fluid changes . |
| Blood biomarker changes of neurological impact | Up to 3 months | Markers of neurological impact - in relation to cerebrospinal fluid changes . |
| Neuroradiological changes | Up to 3 months | Neurological impact in relation to cerebrospinal fluid changes |
| The association between changes in coagulation factors and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder | Up to 12 months | — |
| Clinical course - Lung function recording | Up to 3 months | in relation to cerebrospinal fluid changes/blood |
| Patient characteristics | Up to 3 months | Patient ICU care data - in relation to cerebrospinal fluid changes |
| Clinical course - Pulmonary gas exchange | Up to 3 months | in relation to cerebrospinal fluid changes/blood |
| The association between changes in coagulation ability (ROTEM analysis - rotational thromboelastometry) and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder | Up to 12 months | — |
| The association between changes in inflammatory biomarkers and the presence of neuroradiologically verified brain injury and / or neurocognitive disorder | Up to 12 month | — |
Countries
Sweden
Contacts
Primary ContactLars I Eriksson, Professor
Backup ContactMia Kivipelto, Professor
Outcome results
None listed